KR20140060274A - 안구용 서방성 단백질 전달 제형 및 이의 제조방법 - Google Patents

안구용 서방성 단백질 전달 제형 및 이의 제조방법 Download PDF

Info

Publication number
KR20140060274A
KR20140060274A KR1020147000443A KR20147000443A KR20140060274A KR 20140060274 A KR20140060274 A KR 20140060274A KR 1020147000443 A KR1020147000443 A KR 1020147000443A KR 20147000443 A KR20147000443 A KR 20147000443A KR 20140060274 A KR20140060274 A KR 20140060274A
Authority
KR
South Korea
Prior art keywords
formulation
tocopherol
atec
plga
citrate
Prior art date
Application number
KR1020147000443A
Other languages
English (en)
Korean (ko)
Inventor
버넌 쥐. 웡
루이스 엘. 우드
글렌 티. 황
Original Assignee
램스코르 인코포레이티드
아이콘 바이오사이언스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 램스코르 인코포레이티드, 아이콘 바이오사이언스, 인크. filed Critical 램스코르 인코포레이티드
Publication of KR20140060274A publication Critical patent/KR20140060274A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020147000443A 2011-06-10 2012-06-11 안구용 서방성 단백질 전달 제형 및 이의 제조방법 KR20140060274A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10
US61/495,672 2011-06-10
PCT/US2012/041950 WO2013036309A2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Publications (1)

Publication Number Publication Date
KR20140060274A true KR20140060274A (ko) 2014-05-19

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147000443A KR20140060274A (ko) 2011-06-10 2012-06-11 안구용 서방성 단백질 전달 제형 및 이의 제조방법

Country Status (21)

Country Link
US (1) US9814773B2 (es)
EP (1) EP2717914B1 (es)
JP (1) JP6339011B2 (es)
KR (1) KR20140060274A (es)
CN (1) CN103945865B (es)
AU (1) AU2012304909B2 (es)
BR (1) BR112013031685B1 (es)
CA (1) CA2838289C (es)
CY (1) CY1122771T1 (es)
DK (1) DK2717914T3 (es)
ES (1) ES2761340T3 (es)
HR (1) HRP20192276T1 (es)
HU (1) HUE047737T2 (es)
IN (1) IN2013MN02384A (es)
LT (1) LT2717914T (es)
MX (1) MX359119B (es)
PL (1) PL2717914T3 (es)
PT (1) PT2717914T (es)
RS (1) RS60051B1 (es)
SI (1) SI2717914T1 (es)
WO (1) WO2013036309A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105407896B (zh) * 2013-05-24 2019-08-27 爱康生物科技有限公司 缓释的地塞米松在白内障手术后的炎症中的应用
AU2015257651B2 (en) * 2014-05-08 2020-01-23 Panoptes Pharma Ges.M.B.H. Compounds for treating ophthalmic diseases and disorders
CA2979971A1 (en) * 2015-03-18 2016-09-22 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
AR105215A1 (es) * 2015-07-01 2017-09-13 Santen Pharmaceutical Co Ltd Formulación de depósito que contiene ésteres de ácido cítrico
TWI718168B (zh) * 2015-08-03 2021-02-11 愛爾蘭商托爾瑪國際有限公司 供延長投藥用之液態聚合物遞送系統
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
US11097061B2 (en) 2018-02-09 2021-08-24 Icon Bioscience, Inc. Systems, kits and methods for loading and delivering a small volume dose from a syringe
BR112020022087A2 (pt) 2018-05-01 2021-02-02 Chibi, Inc. depot líquido para liberação prolongada de um agente ativo no olho, conjunto, e, métodos para tratar uma doença ocular em um indivíduo e para prover um revestimento protetor para o olho.
CA3097926A1 (en) 2018-05-01 2019-11-07 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
US11439685B2 (en) 2020-05-22 2022-09-13 Trustees Of Boston University Formulations for treating a fibrotic disease
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
US20240277654A1 (en) 2021-07-06 2024-08-22 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
WO2002000137A1 (en) * 2000-06-28 2002-01-03 Shukla Atul J Biodegradable vehicles and delivery systems of biologically active substances
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
KR20060023140A (ko) * 2003-05-30 2006-03-13 알자 코포레이션 이식성 탄성중합체 데포 조성물, 이의 용도 및 이의제조방법
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
AU2005292145C1 (en) * 2004-10-01 2011-07-21 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP1804751A2 (en) * 2004-10-04 2007-07-11 QLT USA, Inc. Ocular delivery of polymeric delivery formulations
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2792484C (en) * 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
EP2269663B1 (en) * 2009-07-03 2018-03-07 Armbruster Biotechnology GmbH Bone graft and biocomposite

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지

Also Published As

Publication number Publication date
EP2717914B1 (en) 2019-10-30
US20140140992A1 (en) 2014-05-22
JP6339011B2 (ja) 2018-06-06
JP2014516087A (ja) 2014-07-07
CN103945865B (zh) 2016-10-26
CA2838289A1 (en) 2013-03-14
MX2013014461A (es) 2014-05-14
LT2717914T (lt) 2020-03-25
HRP20192276T1 (hr) 2020-05-15
PL2717914T3 (pl) 2020-05-18
NZ619707A (en) 2015-01-30
PT2717914T (pt) 2019-12-18
ES2761340T3 (es) 2020-05-19
RS60051B1 (sr) 2020-04-30
MX359119B (es) 2018-09-14
BR112013031685B1 (pt) 2021-04-06
BR112013031685A2 (pt) 2017-02-07
EP2717914A2 (en) 2014-04-16
AU2012304909A1 (en) 2013-12-19
SI2717914T1 (sl) 2020-07-31
CN103945865A (zh) 2014-07-23
WO2013036309A2 (en) 2013-03-14
DK2717914T3 (da) 2020-01-20
IN2013MN02384A (es) 2015-06-12
AU2012304909B2 (en) 2017-06-08
EP2717914A4 (en) 2015-05-13
WO2013036309A3 (en) 2013-05-10
CY1122771T1 (el) 2021-05-05
US9814773B2 (en) 2017-11-14
CA2838289C (en) 2019-09-10
HUE047737T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
KR20140060274A (ko) 안구용 서방성 단백질 전달 제형 및 이의 제조방법
JP5682991B2 (ja) 便利に移植可能な徐放性薬物処方物
Giri et al. Prospects of pharmaceuticals and biopharmaceuticals loaded microparticles prepared by double emulsion technique for controlled delivery
Choonara et al. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases
US8877229B2 (en) Controlled release microparticles
US20090092650A1 (en) Sustained Delivery Formulations of Octreotide Compounds
JP2007535536A (ja) 高分子含有持続放出眼内インプラントおよび関連方法
US20240165017A1 (en) Bioerodible polyester polymer axitinib ocular implants and related methods of use
NZ619707B2 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
TWI439293B (zh) 便利植入式持續釋放型藥學組合物
Kimura et al. Biodegradable systems

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid